Edesa Biotech (EDSA) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Werewolf Therapeutics (HOWL) over the past year, gaining 34.6% versus a loss of 51.6%. Over five years, EDSA leads with a -93.3% price change compared with -94.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($47.6 million vs $47.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | HOWL |
|---|---|---|
| Share price | $3.51 | $0.9796 |
| Market cap | $47.43M | $47.61M |
| 1-day change | -4.10% | +7.65% |
| YTD return | +157.75% | +43.53% |
| 1-year return | +34.56% | -51.60% |
| 5-year return | -93.31% | -94.67% |
| EPS (TTM) | $-1.72 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $1.85 |
| 52-week low | $0.72 | $0.27 |
| Distance from 52-week high | -82.73% | -47.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +365.24% | +614.58% |
| Average volume | 61.89K | 6.80M |
| Shares outstanding | 13.51M | 48.60M |
| Employees | 17 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed HOWL by 86.2 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
EDSA vs HOWL FAQ
Which is bigger, Edesa Biotech or Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $47.61M compared with $47.43M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or HOWL?
EDSA returned +34.56% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.